K

KeyMed Biosciences Inc
HKEX:2162

Watchlist Manager
KeyMed Biosciences Inc
HKEX:2162
Watchlist
Price: 55.65 HKD -0.27%
Market Cap: HK$16.6B

Wall Street
Price Targets

Price Targets Summary
KeyMed Biosciences Inc

Wall Street analysts forecast KeyMed Biosciences Inc stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KeyMed Biosciences Inc is 84.97 HKD with a low forecast of 71.46 HKD and a high forecast of 98.18 HKD.

Lowest
Price Target
71.46 HKD
28% Upside
Average
Price Target
84.97 HKD
53% Upside
Highest
Price Target
98.18 HKD
76% Upside
KeyMed Biosciences Inc Competitors:
Price Targets
TENB
Tenable Holdings Inc
69% Upside
LGI
Lgi Ltd
34% Upside
PWP
Perella Weinberg Partners
5% Upside
BCBP
BCB Bancorp Inc
33% Upside
EOLS
Evolus Inc
297% Upside
FBIZ
First Business Financial Services Inc
8% Upside
RCKT
Rocket Pharmaceuticals Inc
129% Upside

Revenue
Forecast

N/A
Past Growth
64% / Year
Estimated Growth
Estimates Accuracy
13%
Average Beat
N/A
Past Growth
64% / Year
Estimated Growth
Estimates Accuracy
13%
Average Beat

The compound annual growth rate of KeyMed Biosciences Inc's revenue for the next 4 years is 64%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
27%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
27%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is KeyMed Biosciences Inc's stock price target?
Price Target
84.97 HKD

According to Wall Street analysts, the average 1-year price target for KeyMed Biosciences Inc is 84.97 HKD with a low forecast of 71.46 HKD and a high forecast of 98.18 HKD.

What is KeyMed Biosciences Inc's Revenue forecast?
Projected CAGR
64%

The compound annual growth rate of KeyMed Biosciences Inc's revenue for the next 4 years is 64%.

Back to Top